Western Blot: CDT1 Antibody [NB100-2567] - Human B cells. KSHV infection protects CDT1 from hypoxia mediated degradation. Mock or KSHV infected cells were grown under normoxic or hypoxic condition followed by measuring ...read more
Immunohistochemistry-Paraffin: CDT1 Antibody [NB100-2567] - Human islet cell carcinoma. Antibody used at a dilution of 1:1000 (1ug/mL).
Western Blot: CDT1 Antibody [NB100-2567] - Whole cell lysate from HeLa (5, 15 and 50 ug for WB; 1 mg for IP, 20% of IP loaded) and 293T (T; 50 ug) cells. Affinity purified rabbit anti- CDT1 antibody (NB100-2567) used ...read more
The immunogen recognized by this antibody maps to a region between residue 500 and the C-terminus (residue 546) of human Chromatin Licensing and DNA Replication Factor 1 using the numbering given in entry NP_112190.1 (GeneID 81620).
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.
60.4 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Geminin is a protein that inhibits DNA replication by preventing the loading of MCM complex on chromatin. Human CDT1 is a 65kDa protein that contains 546 amino acids and coimmunoprecipitates with Geminin. Inhibition of DNA replication by Geminin in cell-free cDNA replication extracts can be reversed by the addition of excess CDT1. In the normal cell cycle, CDT1 is present only in G1 and S phases, whereas Geminin is present in S and G2 phases. Wohlschlegel et al. (2000) concluded that their results suggest that Geminin inhibits inappropriate origin firing by targeting CDT1. This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animals cells produce the protein, which stimulates the animals immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Fixed in 4% PFA for 10 min, permeablized in.2% Triton X-100 in PBS for 15 min, blocked for 1 hr in 1% BSA + 10% FBS in PBS with.1% Triton X-100. Incubated in antibody at 1:100 dilution in blocking buffer, and detected with anti-rabbit secondary antibody.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.